0.180
0.01 (5.23%)
| Previous Close | 0.171 |
| Open | 0.171 |
| Volume | 40,158 |
| Avg. Volume (3M) | 1,209,312 |
| Market Cap | 852,424 |
| Price / Sales | 0.100 |
| Price / Book | 0.100 |
| 52 Weeks Range | |
| Earnings Date | 30 Mar 2026 |
| Operating Margin (TTM) | -255.98% |
| Diluted EPS (TTM) | -2.23 |
| Quarterly Revenue Growth (YOY) | -39.30% |
| Total Debt/Equity (MRQ) | 92.65% |
| Current Ratio (MRQ) | 1.03 |
| Operating Cash Flow (TTM) | -15.78 M |
| Levered Free Cash Flow (TTM) | 5.61 M |
| Return on Assets (TTM) | -30.92% |
| Return on Equity (TTM) | -162.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | ProPhase Labs, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 7.99% |
| % Held by Institutions | 11.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sykon Capital Llc | 31 Dec 2025 | 64,478 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative |
| 02 Feb 2026 | Announcement | Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd |
| 26 Jan 2026 | Announcement | ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture |
| 22 Jan 2026 | Announcement | ProPhase Labs Uplists from Pink Sheets to OTC Market |
| 05 Jan 2026 | Announcement | ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value |
| 5Y Average Dividend Yield | 0.21% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 24 May 2022 | 09 May 2022 | 03 Jun 2022 | 0.3 Cash |
| 28 Feb 2022 | 14 Feb 2022 | 10 Mar 2022 | 0.3 Cash |
| 24 May 2021 | 12 May 2021 | 03 Jun 2021 | 0.3 Cash |
| 02 Dec 2019 | 20 Nov 2019 | 12 Dec 2019 | 0.25 Cash |
| 09 Jan 2019 | 24 Dec 2018 | 24 Jan 2019 | 0.25 Cash |
| 06 Jun 2018 | 07 May 2018 | 05 Jun 2018 | 1 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2022 | 0.600 | 2 | 0.62 |
| 2021 | 0.300 | 1 | 0.42 |
| 2019 | 0.500 | 2 | 2.54 |
| 2018 | 1.00 | 1 | 3.18 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |